Citations 2
ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae
Good, Caryn E., Hujer, Andrea M. , Abdelhamed, Ayman M., Rhoads, Daniel D. , Hujer, Kristine M., Rudin, Susan D., Connolly, Lynn, Krause, Kevin M. , Patel, Robin , Arias, César A. , Kreiswirth, Barry N. , Rojas, Laura J. , D’Souza, Roshan , White, Richard C. , Brinkac, Lauren , Nguyen, Kevin , Singh, Indresh , Fouts, Derrick E. , Group, for the Antibacterial Resistance Leadership, Patel, Robin , Fouts, Derrick E , van Duin, David , Rhoads, Daniel D , Jacobs, Michael R. , Domitrovic, Tatiana , Arias, César A. , Kreiswirth, Barry N , Bonomo, Robert A. , Group, for the Antibacterial Resistance Leadership
Antimicrobial Agents and Chemotherapy | March 5, 2020 | Volume: 64 | Issue: 5 | Pages: No page available
Plazomicin was tested against 697 recently acquired carbapenem-resistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC 50 and MIC 90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of >32 mg/liter). Resistance was associated with rmtF -, rmtB -, or armA -encoded 16S rRNA methyltransferases in all except 1 isolate.
In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli
Cunningham, Scott A. , Cole, Nicolynn C., Kohner, Peggy C., Menon, Sanjay , Krause, Kevin M. , Harris, Kelly , De, Partha Pratim, Koh, Tse Hsien , Patel, Robin , Vasoo, Shawn , Patel, Robin , Cunningham, Scott A
Antimicrobial Agents and Chemotherapy | September 22, 2015 | Volume: 59 | Issue: 12 | Pages: 7842-7846
ABSTRACT Among 177 carbapenemase-producing Gram-negative bacilli (108 KPC, 32 NDM, 11 IMP, 8 OXA-48, 4 OXA-181, 2 OXA-232, 5 IMI, 4 VIM, and 3 SME producers), aztreonam-avibactam was active against all isolates except two NDM producers with elevated MICs of 8/4 and 16/4 mg/liter; ceftazidime-avibactam was active against all KPC-, IMI-, SME-, and most OXA-48 group-producing isolates (93%) but not metallo-β-lactamase producers. Among older and contemporary antimicrobials, the most active were colistin, tigecycline, and fosfomycin, with overall susceptibilities of 88%, 79%, and 78%, respectively.